Tuesday, September 15, 2026

BTC $75,697 ▲ 0.15%

NewsLive Wire Politics World Markets Digital Assets Technology Sports

FranchisesThe Brief The Big Read The Breakdown Crypto Culture

MoreDeFi & On-Chain U.S. Equities Macro & Rates Research

LIVE

ADA$0.195−0.04%ETH$2,401+0.17%LINK$10.90+0.19%SOL$97.04+0.24%BTC$75,697+0.15%XRP$1.28+0.19%S&P 5007,586−0.45%Nasdaq25,982−0.78%Dow52,093−0.63%RUT2,870−0.76%TNX5.00%+0.71%TYX5.36%+0.66%FVX4.83%+0.75%IRX3.96%+0.64%VIX17.20+0.58%GOLD$4,321.80−0.25%SILVER$64.18+0.50%OIL$105.38−0.43%DXY99.67+0.06%NVDA$212.17+0.57%AAPL$331.34−0.52%TSLA$356.58−0.67%META$670.24+0.70%MSFT$497.12−1.64%AMZN$248.42−2.02%GOOGL$344.98−1.26%Fear & Greed51 — NeutralADA$0.195−0.04%ETH$2,401+0.17%LINK$10.90+0.19%SOL$97.04+0.24%BTC$75,697+0.15%XRP$1.28+0.19%S&P 5007,586−0.45%Nasdaq25,982−0.78%Dow52,093−0.63%RUT2,870−0.76%TNX5.00%+0.71%TYX5.36%+0.66%FVX4.83%+0.75%IRX3.96%+0.64%VIX17.20+0.58%GOLD$4,321.80−0.25%SILVER$64.18+0.50%OIL$105.38−0.43%DXY99.67+0.06%NVDA$212.17+0.57%AAPL$331.34−0.52%TSLA$356.58−0.67%META$670.24+0.70%MSFT$497.12−1.64%AMZN$248.42−2.02%GOOGL$344.98−1.26%Fear & Greed51 — Neutral

Tag

revolution medicines

2 articles

Research & Analysis19d ago

Revolution Medicines' Rasonque Doubles Pancreatic Cancer Survival

Approval of the once-daily pill, which extended median survival from 6.7 months to 13 months in late-stage trials, values the company at $46 billion as it targets a previously untreatable protein mutation.

U.S. Equities20d ago

Revolution Medicines' Rasonque Wins FDA Nod in Pancreatic Cancer

Daraxonrasib cleared 6.5 months early with Phase 3 data showing median 13.2-month survival versus 6.7 months on chemotherapy in second-line metastatic pancreatic cancer.